Search results
Results from the WOW.Com Content Network
Alopecia universalis (AU), also known as alopecia areata universalis, is a medical condition involving the loss of all body hair, including eyebrows, eyelashes, chest hair, armpit hair, and pubic hair. It is the most severe form of alopecia areata (AA). [1]
Alopecia areata monolocularis describes baldness in only one spot. It may occur anywhere on the head. Alopecia areata multilocularis refers to multiple areas of hair loss. Ophiasis refers to hair loss in the shape of a wave at the circumference of the head. The disease may be limited only to the beard, in which case it is called alopecia areata ...
Androgenetic alopecia: history of gradual thinning of hair and characteristic pattern. [4] Males start to lose hair in the front and temples while females lose hair at the top of the head; Diffuse alopecia areata: exclamation point hairs [3] Alopecia totalis: concomitant loss of facial and skull hair [6]
Alopecia areata is an autoimmune disorder also known as "spot baldness" that can result in hair loss ranging from just one location (Alopecia areata monolocularis) to every hair on the entire body (Alopecia areata universalis). Although thought to be caused by hair follicles becoming dormant, what triggers alopecia areata is not known.
Alopecia totalis is the loss of all hair on the head and face.Its causes are unclear, but believed to be autoimmune.Research suggests there may be a genetic component linked to developing alopecia totalis; the presence of DRB1*0401 and DQB1*0301, both of which are human leukocyte antigens (HLA), were found to be associated with long-standing alopecia totalis.
Androgenic alopecia also occurs in women, and more often presents as diffuse thinning without hairline recession. Like its male counterpart, the condition rarely leads to total hair loss . Treatment options are similar to those for men, although topical or systemic estrogen is used more often.
And research data from national surveys of American children called the “Youth Risk Behavioral Surveillance System” also wasn’t available on Friday.
The US Food and Drug Administration (FDA) approved ritlecitinib based on evidence from a clinical trial of 718 participants with severe alopecia areata. [11] The efficacy and safety of ritlecitinib were evaluated in a randomized, double-blind, placebo controlled trial in 718 participants twelve years of age and older with alopecia areata with ≥50% scalp hair loss, including alopecia totalis ...